Gaucher Disease
En Español (Spanish Version)

Definition
Gaucher disease is a rare disease. It causes the abnormal storage of fatty substances. These fatty substances build up in the bones, liver, lungs, spleen and occasionally the brain. There are three types of Gaucher disease:

  • Type I—most common, found widely in people of Ashkenazi Jewish descent
  • Type II—rare, rapidly progressive form
  • Type III—rare, most cases found in Japan and Scandinavia
Causes
Gaucher disease is a genetic disease. A faulty gene limits the amount of an enzyme called glucocerebrosidase. The enzyme normally breaks down a fat called glucocerebroside. There is not enough of the enzyme to break down all of this specific fat. As a result, it builds up in the spleen, liver, lungs, bones, and brain.

Risk Factors
A family history of Gaucher is the only known factor that increases your risk of Gaucher.

Symptoms
Symptoms vary across the three types of Gaucher disease. In general, the later the onset of symptoms, the less likely that symptoms will be severe.

Type I symptoms may include:
  • Fatigue
  • Easy bruising
  • Slow or stunted growth in children
  • Intestinal problems like abdominal swelling
  • Trouble breathing
  • Seizures
  • Vision problems
  • Developmental delays
Spleen

Copyright © Nucleus Medical Media, Inc.

Types II and III also have additional symptoms.

In type II, rigidity and seizures may appear within the first few months of life. Dementia and intellectual disabilities may appear later. This type is usually fatal by the age of three.

In type III, the primary symptom is a slowly progressive neurologic disease. This can include seizures and mental retardation. Other symptoms are similar to type I and may appear in early childhood. People with type III Gaucher who survive through adolescence may survive until their 30s or 40s.

Diagnosis
Your doctor will ask about symptoms and medical history. A physical exam will be done.

Your bodily fluids and tissue may be tested. This can be done with:

  • Blood tests
  • Tissue biopsy
  • Urine tests
Treatment
There is no treatment for the severe neurologic symptoms that may occur with type II and type III Gaucher.

Treatment options for type I Gaucher include:

Medications
Certain medications can be used to replace the missing enzyme. This enzyme replacement therapy will be given through regular infusions. This therapy can help reduce abnormalities in the bone, decrease liver and spleen size, and reverse some abnormal blood counts.

Medications that reduce the amount of fatty acids in the blood may be effective for people who cannot tolerate enzyme replacement therapy.

Medications may also be given for bone pain and to relieve bone crises.

A transplant is used only in patients with severe neurological symptoms.

Bone Marrow Harvest

Copyright © Nucleus Medical Media, Inc.

An enlarged spleen may need to be removed. It can lead to other health problems if it is enlarged and not removed.

Prevention
There is no known way to prevent Gaucher disease. If you have Gaucher disease or have a family history of the disorder, you can talk to a genetic counselor. They can help determine the risk of Gaucher disease in your offspring.




RESOURCES:
Gauchers Association

National Gaucher Foundation

CANADIAN RESOURCES:

The National Gaucher Foundation of Canada

References:
About Gaucher. Gauchers Association website. Available at: http://www.gaucher.org.uk/about_gaucher. Accessed August 13, 2013.

Gaucher disease. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/what.php. Updated March 4, 2013. Accessed August 13, 2013.

Gaucher disease. National Gaucher Foundation website. Available at: http://www.gaucherdisease.org. Accessed August 13, 2013.

Recommendations on the diagnosis, treatment, and monitoring of Gaucher disease. Martins AM, Valadares ER, Porta G, et al. J Pediatrics. 2009;155(4 Suppl):S10-S18.

Shire announces FDA approval of VPRIV (velaglucerase alfa for injection) for the treatment of type 1 Gaucher disease. PR Newswire website. Available at: http://www.prnewswire.com/news-releases/shire-announces-fda-approval-of-vprivtm-velaglucerase-alfa-for-injection-for-the-treatment-of-type-1-gaucher-disease-85554402.html Published February 26, 2010. Accessed August 13, 2013.

3/5/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php : FDA approves therapy to treat Gaucher disease. US Food and Drug Administration website. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm202288.htm. Published February 26, 2010. Accessed March 5, 2010.

Last Reviewed August 2013



Health Information Library content is provided by EBSCO Publishing, fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.

 

This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.

 

To send comments or feedback to EBSCO's Editorial Team regarding the content please e-mail healthlibrarysupport@ebscohost.com.